Pharma companies are increasingly relying on academic and nonprofit collaborations for basic science and drug discovery research, and some big players have formed some notable unions in 2014.
Longtime Alzheimer's player Eli Lilly has agreed to pay $50 million in a near-term milestone and take charge of the development work in a collaboration package worth a total of up to $500 million.
Hospitals affiliated with Stanford and Duke University are initiating partnerships with Apple and its yet to be unveiled HealthKit, designed to collect data from healthcare apps and present it to doctors in a centralized location.
CRO magnate Icon and and eClinical outfit Medidata are pooling their resources to offer a combined platform for patient-reported outcomes in clinical trials, touting their technology as faster and more effective in surveying participants.
Nonprofit researcher SRI International has struck a deal with Japanese drugmaker Nobelpharma to collaborate on a new treatment for the painful gynecological disease endometriosis.
AliveCor, the maker of the first FDA-approved smartphone-based device to detect atrial fibrillation, is partnering with Apollo Hospitals to provide the monitor to patients throughout India.
The Defense Advanced Research Projects Agency awarded Harvard University engineers up to $2.9 billion to develop a robotic suit to make walking easier for soldiers and potentially civilians with disabilities, the university announced today.
Blackberry is launching an ambitious project to integrate thousands of medical devices in India in order to detect illnesses earlier.
Genmab is taking its cancer drug collaboration with Seattle Genetics one more step forward. The Danish biotech is handing over an $11 million upfront and promising up to $200 million more to get the right to use Seattle Genetics' antibody-drug conjugate technology for its HuMax-AXL program.
Ophthotech says it won a $50 million enrollment milestone from Novartis for reaching a goal on its Phase III Fovista study for wet, age-related macular degeneration.